课题基金 / 基金详情

Molecular mechanism of nasopharyngeal carcinoma oncogenesis by Epstein-Barr virus RNA EBERs

Molecular mechanism of nasopharyngeal carcinoma oncogenesis by Epstein-Barr virus RNA EBERs
Epstein-Barr病毒RNA EBERs导致鼻咽癌发生的分子机制
批准号:
13671775
负责人:
YOSHIZAKI Tomokazu
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

YOSHIZAKI Tomokazu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
EBERs is composed of EBER1 and EBER2. Transfection of EBER1+EBER2 expression vector in MDCK cell enhanced colony formation in soft agar, indicating that expression of EBERs transformed MDCK cell to potentially malignant, anchor-independent phenotype. Either EBER1 or EBER2 expression alone was not sufficient for transformation of MDCK cell to this anchor-independent character. EBERs did not protect MDCK cells from dell death in the condition of serum starvation and irradiation. EBERs are known to activates protein kinase R(PKR) which is activated by double-strand RNA. However, our in vitro kination assay revealed that EBERs did not activate PKR in MDCK cells. These results suggest that transformation of MDCK by EBERs were mediated by alternative pathway rather than PKR pathway. Expression of EBERs in nasopharyngeal carcinoma tissue tended to be correlated with advanced T stage, suggesting that EBERs promote growth and proliferation of tumor cell in nasopharyngeal carcinoma.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Maekawa K, Sato H, Furukawa M, Yoshizaki T.: "Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model."Clin Exp Metastasis. 19(6). 513-518 (2002)
Maekawa K、Sato H、Furukawa M、Yoshizaki T.:“在原位口腔鳞状细胞癌植入模型中,marimastat (BB-2516) 对颈部淋巴结转移的抑制。”Clin Exp 转移。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
吉崎 智一: "上咽頭癌転移関連遺伝子発現と遺伝子治療の可能性-アスピリンは転移を抑制するか-"日本耳鼻咽喉科学会会報. 104. 791-795 (2001)
Tomokazu Yoshizaki:“鼻咽癌转移相关基因表达和基因治疗的可能性 - 阿司匹林会抑制转移吗?”日本耳鼻喉科学会通报 104. 791-795 (2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoshizaki, T., Maruyama, Y., Sato, H., Furukawa, M.: "Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrx metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma"Int. J. Cancer. 95. 44
Yoshizaki, T.、Maruyama, Y.、Sato, H.、Furukawa, M.:“基质金属蛋白酶-2 组织抑制剂的表达与基质金属蛋白酶-2 的激活相关,并预测舌鳞状细胞癌的不良预后”Int。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
17
    Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma
    • 批准号:
      23659792
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.0万
    • 财政年份:
      2011
    • 负责人:
      YOSHIZAKI Tomokazu
    • 依托单位:
    The role of intrinsic immunity for EBV-mediated nasopharyngeal carcinogenesis
    • 批准号:
      23390396
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.74万
    • 财政年份:
      2011
    • 负责人:
      YOSHIZAKI Tomokazu
    • 依托单位:
    Development of molecular targeting therapy for head and neck cancer by targeting membrane type MMP and EBV antigen
    • 批准号:
      15390514
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $6.98万
    • 财政年份:
      2003
    • 负责人:
      YOSHIZAKI Tomokazu
    • 依托单位:
    国内基金
    海外基金
    EB病毒EBERs和BARF1基因变异型参与鼻咽癌癌变的分子机制研究
    • 批准号:
      81171571
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2011
    • 负责人:
      王云
    • 依托单位: